CATNON interim results: another triumph of upfront chemotherapy in glioma

According to the World Health Organization (WHO) 2016 classification of central nervous system tumors,¹ diffuse gliomas are no longer classified based on morphological features alone but also on molecular markers with strong diagnostic and prognostic value, namely, the presence or absence of isocitrate dehydrogenase (IDH1/2) mutations and 1p/19q codeletion. Non-codeleted 1p/19q anaplastic gliomas represent a subtype of tumors with worse prognosis than their 1p/19q codeleted counterparts and are thought to be less sensitive to chemotherapy.^2,3 Optimal treatment of WHO grade III gliomas and, particularly, the role of adjuvant chemotherapy after irradiation have been the subjects of much debate, leading to high variability in patient management.

http://ift.tt/2eSt2ja